NASDAQ:AMRN
Amarin Corporation PLC Stock News
$0.88
-0.0047 (-0.532%)
At Close: Apr 24, 2024
Amarin's (AMRN) Q4 Preliminary Revenues Top Expectations
08:19pm, Wednesday, 11'th Jan 2023
Amarin Corporation (AMRN) expects to generate total revenues in the range of $88-$90 million in fourth-quarter 2022. Share price rises following the announcement.
Amarin Corporation plc (AMRN) Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)
11:26pm, Tuesday, 10'th Jan 2023
Amarin Corporation plc (NASDAQ:AMRN ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 8:15 PM ET Company Participants Karim Mikhail - President and Chief Executive Officer Tom Reilly -
Amarin's stock is up 17% on strong revenue estimates for 2022
12:40pm, Tuesday, 10'th Jan 2023
U.S.-listed shares of Amarin Corp. PLC AMRN, +16.22% rallied about 17% in trading on Tuesday afternoon after the company shared better-than-expected sales estimates for 2022. In a news release and dur
Penny Stocks To Buy In 2023? 3 To Watch In January
11:01am, Friday, 06'th Jan 2023
3 penny stocks to watch this week. The post Penny Stocks To Buy In 2023?
GSK Signs Deal to Develop Antibodies for Treating Cancer
06:09pm, Thursday, 05'th Jan 2023 Zacks Investment Research
GSK (GSK) partners with WuXi Biologics to develop bi- & multi-specific T-cell engaging antibodies. GSK will have an exclusive license to develop and commercialize these candidates.
BioMarin's (BMRN) Voxzogo Expanded Label Filing Accepted by EMA
04:10pm, Wednesday, 04'th Jan 2023 Zacks Investment Research
The EMA validates BioMarin's (BMRN) label expansion filing for Voxzogo to treat children under two years with achondroplasia. BMRN submits a filing for using Voxzogo in children under five years.
Magenta (MGTA) Down on Pipeline Update for Leukemia Drug
12:39pm, Wednesday, 21'st Dec 2022 Zacks Investment Research
Magenta Therapeutics (MGTA) stops dosing participants in a phase I/II study cohort, evaluating its blood cancer pipeline candidate due to dose-limiting toxicities.
LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China
03:20pm, Tuesday, 20'th Dec 2022 Zacks Investment Research
As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone
Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 14'th Dec 2022
DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin's president and chief executive officer, is sch
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
01:30pm, Wednesday, 07'th Dec 2022 GlobeNewswire Inc.
-- Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 -- -- Swissmedic Approval Underpins Company’s Presence and Expansion in Switzerland
Why Amarin (AMRN) Stock Might be a Great Pick
01:42pm, Monday, 21'st Nov 2022 Zacks Investment Research
Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why Amarin (AMRN) Stock Might be a Great Pick
09:47am, Monday, 21'st Nov 2022
Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Amarin Corporation plc (AMRN) Presents at 13th Annual Jefferies London Healthcare Conference 2022 (Transcript)
03:27pm, Wednesday, 16'th Nov 2022
Amarin Corporation plc (NASDAQ:AMRN ) 13th Annual Jefferies London Healthcare Conference 2022 November 16, 2022 9:40 AM ET Company Participants Karim Mikhail - President and Chief Executive Officer To
Why Amarin Stock Was a Winner Today
10:53pm, Tuesday, 15'th Nov 2022 The Motley Fool
The product most readily identified with the company will soon hit pharmacy shelves in Australia.
Why Amarin Stock Was a Winner Today
05:53pm, Tuesday, 15'th Nov 2022
The product most readily identified with the company will soon hit pharmacy shelves in Australia.
